Review: Sparse high-quality evidence supports surgery for obesity

September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p51
Academic Journal
The article presents a study on surgical treatment of obesity. Researchers assessed randomized controlled trials, controlled clinical trials, cohort studies, and case series that evaluated surgical treatment of obesity. The analysis focused on the most common currently performed surgical procedures. The most recent high-quality evidence was from a large, matched-cohort study, showing greater weight loss at 8 years and at 10 years with surgery than with non-surgical therapy. A cohort study showed a reduction in hypertension, diabetes, and dyslipidemia in surgically treated patients at 24 months compared with a non surgical control group.


Related Articles

  • Review: Several pharmacologic therapies promote modest weight loss. Kennel, Kurt A. // ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p50 

    The article presents information about the pharmacologic treatment of obesity. Researchers selected randomized controlled trials that evaluated pharmaceutical agents for weight loss in patients with body mass index. Study quality was assessed using the 5-point Jadad scale and considered study...

  • Mechanisms of Weight Loss After Bariatric Surgery. Flancbaum, Louis // Journal of Laparoendoscopic & Advanced Surgical Techniques;Aug2003, Vol. 13 Issue 4, p215 

    The surgical treatment of clinically severe obesity is becoming more popular. To date, little has been published concerning the mechanisms by which each of the commonly employed bariatric surgical procedures induces weight loss. This article reviews the physiology of weight loss induced by...

  • Pharmacologic and Surgical Treatment of Obesity. Morantz, Carrie; Torrey, Brian // American Family Physician;12/1/2004, Vol. 70 Issue 11, p2225 

    Presents information on a report by the U.S. Agency for Healthcare Research and Quality entitled "Pharmacological and Surgical Treatment of Obesity." Examples of health problems experienced by extremely obese persons; Percentage of patients who experience minor complications after weight-loss...

  • 2. Recommendations on obesity and weight loss. Leiter, Lawrence A.; Abbott, Darlene; Campbell, Norman R.C.; Mendelson, Rena; Ogilvie, Richard I.; Chockalingam, Arun // CMAJ: Canadian Medical Association Journal Supplement;5/4/1999 Hypertension, Vol. 160 Issue 9, pS7 

    Presents a study to provide updated, evidence-based recommendations concerning the effects of weight-loss and maintenance of healthy weight on the prevention and control of hypertension in otherwise healthy adults (except pregnant women). Options; Outcomes; Evidence; Values; Benefits, harms and...

  • Trials Set for Eli Lilly's Five Obesity Compounds. Tolchin, Elizabeth // Drug Discovery & Development;Jun2004, Vol. 7 Issue 6, p22 

    Provides information on the clinical trial candidates of Eli Lilly & Co. in Indianapolis for treatment of obesity. Development of the drugs by the company; Efficacy of the drugs; Use of animal models for testing the drugs; Aim for the drugs.

  • SHORT CUTS.  // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/27/2009, Vol. 338 Issue 7710, p1526 

    The article discusses the findings of several clinical studies published in different medical journals in Great Britain. A randomised trial to test a theory that extra dietary calcium could help sequester fat within the gut resulting in weight loss, has revealed that taking this extra calcium...

  • Fenugreek For Blood Sugar and Weight Loss Management. Mathern, Jocey // Total Health;Oct/Nov2003, Vol. 25 Issue 5, 'Special section' p13 

    Evaluates the health benefits of Fenugreek for blood sugar control and weight loss management. Mechanism of action of FenuLife, a fenugreek extract; Comparison of the therapeutic effect of psyllium husk powder concentration and fenugreek extract; Physiologic effects of fenugreek.

  • OBESITY TREATMENTS. Haslam, David // Pulse;10/31/2007, Vol. 67 Issue 39, p40 

    The author discusses several information on treatments for obesity. The author talks about the therapeutics that can be applied in alleviating corpulence. He includes the historical background for obesity treatment including mercury, arsenic, and strychnine. At the same time, he also cites the...

  • First Qnexa Phase III Trial Hits Endpoints.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p4 

    The article reports on the result of the first of three Phase III trials of Vivus Inc.'s obesity drug Qnexa. It demonstrates an average weight loss of 9.2% at a full-dose and 8.5 % at the mid-dose in comparison to the 1.7% for the placebo group. Results also show that Qnexa may fare better than...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics